Risk of hospitalization and use of first-versus second-generation antipsychotics among nursing home residents

Psychiatric Services

Volumn 65, Issue 6, 2014, Pages 781-788

  Aparasu, Rajender R ^a   Chatterjee, Satabdi ^a   Chen, Hua ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

AGED; ARTICLE; COMPARATIVE STUDY; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; NURSING HOME PATIENT; PRESCRIPTION; PROPENSITY SCORE; RISK FACTOR; VERY ELDERLY; COHORT ANALYSIS; NURSING HOME; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TIME; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MEDICAID; MEDICARE; NURSING HOMES; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 84901936009     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201300093     Document Type: Article

References (39)

1. Bagnall AM, Jones L, Ginnelly L, et al: A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technology Assessment 7:1-193, 2003
2. Jeste DV, Dolder CR, Nayak GV, et al: Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature. Harvard Review of Psychiatry 13:340-351, 2005 (Pubitemid 43048618)
3. Carson S, McDonagh MS, Peterson K: A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. Journal of the American Geriatrics Society 54:354-361, 2006
4. Alexopoulos GS, Streim J, Carpenter D, et al: Using antipsychotic agents in older patients. Journal of Clinical Psychiatry 65 (suppl 2):5-99, 2004
5. Medicare Atypical Antipsychotic Drug Claims for Elderly Nursing Home Residents. Pub no OEI-07-08-00150. Washington, DC, US Department of Health and Human Services, Office of Inspector General, May 2011. Available at oig.hhs. gov/oei/reports/oei-07-08-00150.pdf
6. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353: 1209-1223, 2005 (Pubitemid 41345943)
7. Jones PB, Barnes TRE, Davies L, et al: Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 63:1079-1087, 2006 (Pubitemid 44498387)
8. Kirshner HS: Controversies in behavioral neurology: the use of atypical antipsychotic drugs to treat neurobehavioral symptoms in dementia. Current Neurology and Neuroscience Reports 8:471-474, 2008
9. Trifirò G, Spina E, Gambassi G: Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Pharmacological Research 59:1-12, 2009
10. Henderson DC: Managing weight gain and metabolic issues in patients treated with atypical antipsychotics. Journal of Clinical Psychiatry 69:e04, 2008
11. Baker RA, Pikalov A, Tran QV, et al: Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration adverse event database: a systematic Bayesian signal detection analysis. Psychopharmacology Bulletin 42:11-31, 2009
12. Ray WA, Chung CP, Murray KT, et al: Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine 360:225-235, 2009
13. Public Health Advisory: Deaths With Antipsychotics in Elderly Patients With Behavioral Disturbances. Silver Spring, Md, US Food and Drug Administration, 2013. Available at www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationfor- HeathcareProfessionals/PublicHealthAdvisories/ ucm053171.htm. Accessed Dec 3, 2010
14. Information for Healthcare Professionals: Conventional Antipsychotics. Silver Spring, Md, US Food and Drug Administration, 2013. Available at www.fda.gov/drugs/drugsafety/ postmarketdrugsafetyinformationforpatientsandproviders/ucm124830.htm. Accessed Dec 3, 2010
15. Kennedy J, Tien YY, Cohen LJ, et al: The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey. Clinical Therapeutics 31:2931-2939, 2009
16. Aparasu RR, Jano E, Johnson ML, et al: Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. American Journal of Geriatric Pharmacotherapy 6: 198-204, 2008
17. Simoni-Wastila L, Ryder PT, Qian J, et al: Association of antipsychotic use with hospital events and mortality among Medicare beneficiaries residing in long-term care facilities. American Journal of Geriatric Psychiatry 17:417- 427, 2009
18. Al-Zakwani IS, Barron JJ, Bullano MF, et al: Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Current Medical Research Opinion 19:619-626, 2003 (Pubitemid 37288069)
19. Bagchi AD, Esposito D, Verdier JM: Prescription drug use and expenditures among dually eligible beneficiaries. Health Care Financing Review 28:43-56, 2007 (Pubitemid 47173626)
20. Health Care Spending and the Medicare Program. Washington, DC, Medicare Payment Advisory Commission, June 2010. Available at www.medpac.gov/documents/ Jun10DataBookEntireReport.pdf
21. Dual Eligibles: Medicaid Role in Filling the Gaps. Washington, DC, Kaiser Commission on Medicaid and Uninsured. Available at kaiserfamilyfoundation. files.wordpress.com/2013/01/dual-eligibles-medicaid-s-role-in-filling-medicare- s-gaps.pdf. Accessed Dec 3, 2010
22. Komisar HL, Feder J, Kasper JD: Unmet long-term care needs: an analysis of Medicare-Medicaid dual eligibles. Inquiry 42:171-182, 2005 (Pubitemid 41608307)
23. Medicaid Analytic eXtract (MAX) General Information. Baltimore, Centers for Medicare and Medicaid Services, Oct 2013. Available at www.cms.hhs.gov/ MedicaidData-SourcesGenInfo/07-MAXGeneralInformation.asp. Accessed Dec 3, 2010
24. Standard Analytical Files. Baltimore, Centers for Medicare and Medicaid Services, Dec 2013. Available at www.cms.hhs.gov/IdentifiableDataFiles/02- StandardAnalyticalFiles.asp. Accessed Dec 3, 2010
25. Find a CMS Data File. Minneapolis, Minn, Research Data Assistance Center. Available at www.resdac.umn.edu/Available-CMS-Data.asp. Accessed Dec 3, 2010
26. Ray WA: Evaluating medication effects outside of clinical trials: new-user designs. American Journal of Epidemiology 158: 915-920, 2003
27. Aparasu RR, Chatterjee S, Mehta S, et al: Risk of death in dual-eligible nursing home residents using typical or atypical antipsychotic agents. Medical Care 50:961-969, 2012
28. Schneeweiss S, Setoguchi S, Brookhart A, et al: Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Canadian Medical Association Journal 176: 627-632, 2007 (Pubitemid 46426056)
29. Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-55, 1983
30. Brookhart MA, Schneeweiss S, Rothman KJ, et al: Variable selection for propensity score models. American Journal of Epidemiology 163:1149-1156, 2006 (Pubitemid 43987579)
31. Parson LS: Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques. Edmonds, Wash, Ovation Research Group, 2001. Available at www2.sas.com/proceedings/sugi26/p214-26.pdf
32. Austin PC: Type I error rates, coverage of confidence intervals, and variance estimation in propensity-score matched analyses. International Journal of Biostatistics, 2009; doi 10.2202/1557-4679.1146
33. Alexander MT, Kufera JA: Butting Heads on Matched Cohort Analysis Using SAS Software. Baltimore, University of Maryland School of Medicine, National Study Center for Trauma and Emergency Medical Systems, 2007. Available at www.nesug.org/proceedings/nesug07/sa/sa01.pdf
34. Vittinghoff E, Glidden DV, Shiboski SC, et al: Regression Methods in Biostatistics: Linear, Logistic, Survival and Repeated Measures Models. New York, Springer, 2005
35. Kleinbaum DG: Survival Analysis: A Self- Learning Text. New York, Springer-Verlag, 1996
36. Kapur S, Remington G: Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biological Psychiatry 50: 873-883, 2001 (Pubitemid 34020700)
37. Stahl SM: Describing an atypical antipsychotic: receptor binding and its role in pathophysiology. Primary Care Companion to the Journal of Clinical Psychiatry 5:9-13, 2003
38. Schneeweiss S, Setoguchi S, Brookhart MA, et al: Assessing residual confounding of the association between antipsychotic medications and risk of death using survey data. CNS Drugs 23:171-180, 2009
39. Robins JM, Mark SD, Newey WK: Estimating exposure effects by modelling the expectation of exposure conditional on confounders. Biometrics 48:479-495, 1992